A Multicenter, Open Label Study Of Maraviroc, Zidovudine And Lamivudine Twice Daily For The Treatment Of Antiretroviral Naive HIV-Infected Patients With R5 HIV-1 In Russia.
Phase of Trial: Phase IV
Latest Information Update: 29 Apr 2014
At a glance
- Drugs Lamivudine/zidovudine (Primary) ; Maraviroc (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors ViiV Healthcare
- 10 Jun 2017 Biomarkers information updated
- 24 Jul 2013 Planned end date changed from 1 Jun 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.